Search results
Showing 1251 to 1300 of 2065 results for work
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
In development Reference number: GID-TA11089 Expected publication date: TBC
In development Reference number: GID-TA11299 Expected publication date: TBC
Discontinued Reference number: GID-TA10353
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued Reference number: GID-TA10585
Discontinued Reference number: GID-TAG280
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
In development Reference number: GID-TA11607 Expected publication date: 13 January 2027
In development Reference number: GID-MT538 Expected publication date: TBC
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
Discontinued Reference number: GID-TAG424
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
Discontinued Reference number: GID-TAG425
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
Discontinued Reference number: GID-TAG433
Discontinued Reference number: GID-TA10233
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
In development Reference number: GID-TA10882 Expected publication date: TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]
In development Reference number: GID-TA11022 Expected publication date: TBC
In development Reference number: GID-TA10758 Expected publication date: TBC
In development Reference number: GID-TA11093 Expected publication date: TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]
In development Reference number: GID-TA11044 Expected publication date: TBC
In development Reference number: GID-TA11166 Expected publication date: TBC
New pharmaceutical treatments for non-Alzheimer dementias [ID380]
Discontinued Reference number: GID-TAG369
Discontinued Reference number: GID-TA10033
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
Discontinued Reference number: GID-HST10007
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development Reference number: GID-TA10822 Expected publication date: TBC
In development Reference number: GID-TA11074 Expected publication date: TBC
Discontinued Reference number: GID-TAG437
In development Reference number: GID-TA11585 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
Discontinued Reference number: GID-TA10566
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA937)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Discontinued Reference number: GID-TA11109
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued Reference number: GID-TA10416
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued Reference number: GID-TA10527
In development Reference number: GID-TA11146 Expected publication date: TBC
In development Reference number: GID-HST10020 Expected publication date: TBC
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Discontinued Reference number: GID-TA10841
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
Discontinued Reference number: GID-TAG511
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
Discontinued Reference number: GID-TA10202